The ‘First and Only’ Metastatic Lung Cancer Immunotherapy is approved

19/10/2016 - 2 minutes

Roche’s Genentech has received FDA approval for an immunotherapy targeting the highly sought-after PD-L1. The treatment may be able to outperform its competitors in lung cancer therapies.

roche logoIn May, Roche received approval for Tecentriq (atezolizumab) in bladder cancer. Now, the drug is expanding its indications to become the first and only cancer immunotherapy in the market to target the checkpoint inhibitor Program-Death ligand 1 (PD-L1) in metastatic non-small cell lung cancer (NSCLC).

PD-L1 is a tumor protein that can bind to T-cell PD-1 receptors to inhibit the immune response. Tecentriq inhibits PD-L1 to enhance the ability of the immune system to attack cancer cells. Roche’s new therapy can prolong the patients’ life a median of 4 months longer than chemotherapy, which is an important step forward in patient care.

Everyone’s after checkpoint inhibitors to activate the immune response in cancer. And PD-L1 and its receptor PD-1 are particularly appealing to Biotechs: BMS’ Opdivo used to lead PD-L1 therapies for lung cancer but after failed clinical trials now focuses on leukemia

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member